Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes
February 22 2017 - 6:00PM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it
has agreed to sell $1.5 billion of senior unsecured notes: $750
million in aggregate principal amount of 1.600% notes due 2019 and
$750 million in aggregate principal amount of 3.250% notes due
2027, in an underwritten public offering.
Goldman, Sachs & Co., Morgan Stanley & Co. LLC, Merrill
Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global
Markets Inc. and J.P. Morgan Securities LLC are acting as joint
book-running managers for the offering.
Bristol-Myers Squibb intends to use the proceeds from the
offering to fund its share repurchase program and for general
corporate purposes.
The final prospectus supplement and accompanying prospectus,
when available, may be accessed through the SEC’s website at
https://www.sec.gov/. Alternatively, the issuer, the underwriters
or any dealer participating in the offering will arrange to send
you the prospectus and prospectus supplement if you request it by
calling Goldman, Sachs & Co. at 1-866-471-2526, Morgan Stanley
& Co. LLC at 1-866-718-1649 or Merrill Lynch, Pierce, Fenner
& Smith Incorporated at 1-800-294-1322.
These securities are offered pursuant to a registration
statement that has become effective under the Securities Act of
1933, as amended. These securities are only offered by means of the
prospectus supplement and prospectus relating to the offering. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any offer or
sale of these securities in any state or other jurisdiction, where
the offer, solicitation or sale of these securities would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube and Facebook.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb’s business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb’s Annual Report on Form 10-K for the year ended December 31,
2016 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170222006673/en/
Bristol-Myers Squibb CompanyMedia:Ken Dominski,
609-252-5251ken.dominski@bms.comorInvestors:Tim Power,
609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024